The U.S. Patent and Trademark Office has reaffirmed the Patent Trial and Appeal Board's decision favoring the Broad Institute in the CRISPR/Cas9 patent interference case against the University of California and others. This marks the third time the PTAB has ruled that Broad was the first to invent CRISPR/Cas9 gene editing in human cells, a key technology exclusively licensed to Editas Medicine. The decision strengthens Editas Medicine's intellectual property position as it advances its gene editing therapies, including the promising EDIT-401 for cholesterol reduction. The opposing party, CVC, retains the right to appeal the ruling to the U.S. Court of Appeals for the Federal Circuit.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
